The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...
RSI is also defined as an “AI system capable of fully autonomously designing and developing its own successor,” per Anthropic’s blog post. “We are not there yet, and recursive self-improvement is not ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...
One of the key challenges of current multi-agent AI systems is that they communicate by generating and sharing text sequences, which introduces latency, drives up token costs, and makes it difficult ...
Recursive Superintelligence, a startup founded by former leaders from Meta AI, Google DeepMind, OpenAI, and Salesforce AI, has emerged from stealth with $650 million in funding at a $4.65 billion ...
Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...
Recursive Superintelligence, founded by former Google, Meta and OpenAI researchers, is part of a growing effort to automate the creation of artificial intelligence. By Cade Metz Reporting from San ...
Najat Khan looks at successful platform companies like Vertex, Regeneron and Alnylam and sees a path for Recursion to join them—if the company stays disciplined. (Recursion Pharmaceuticals) Chris ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...
Shares of Recursion Pharmaceuticals (RXRX) spiked on Wednesday after the AI-driven drug developer significantly exceeded Street forecasts with its Q4 2025 financials, thanks primarily to a milestone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results